

ACURATE neo2™
Aortic Valve System

**Boston
Scientific**
Advancing science for life™



Precision today, access tomorrow.



From routine, to challenging.


A valve as versatile as your cases.

Uniquely designed with an **open-frame** and **supra-annular leaflets**, the ACURATE *neo2*TM Valve delivers the performance you expect today, without restricting the access you demand tomorrow.¹

The ACURATE *neo2* Aortic Valve System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.

1. Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent (RE-ACCESS); NCT04026204. *J Am. Coll. Cardiol. Interv.* 2020.

Why TAVI practitioners are switching to the ACURATE *neo2* Valve:



Trusted outcomes.

- Best-in-class PPI
- Single-digit gradients
- Advanced PVL performance

Unrestricted design.

- Unrestricted coronary access
- Long-term hemodynamics
- Engineered to last

Precise procedures.

- Smooth deliverability
- Predictable alignment
- Accurate positioning

Hybrid benefits deliver the “best of both”.


The first of its kind, ACURATE *neo2* is the only valve designed to offer the best benefits of both supra- and intra- valve platforms.

Open-frame design

Provides unrestricted access for future interventions

Supra-annular leaflets

Achieves large EOAs and single-digit gradients¹



Active PVseal™

60% larger* sealing skirt conforms to the native aortic annulus

Accurate positioning

Upper- and lower-crown anchoring provides first-time, precise procedures



*Next-generation ACURATE *neo2* Valve vs. ACURATE *neo*™ Valve

1. Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE *neo2* Valve System for transcatheter aortic valve implantation: 30-day and 1-year outcomes. *Clin Res Cardiol.* 2021;110:1912-1920.



Best-in-class PPI.

Lower your patients’ risk of needing a pacemaker. With top-down deployment and upper- and lower-crown anchoring, ACURATE *neo2* minimizes LVOT protrusion to:¹

- Reduce the risk of new conduction disturbances
- Reduce patient length of stay

6%
new permanent
pacemaker rate*¹
*in hospital

ACURATE *neo2* permanent pacemaker rate among pacemaker-naïve patients at 30 days in the PMCF study: 6.5%²


1. Early *neo2* Registry. Full Core-Lab Results of TAVI with the New ACURATE *neo2* Valve. TVT Congress. Presenter: Andreas Rück. July 20, 2021.
2. Kim W., et al; Clinical outcomes of the ACURATE *neo2* transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, *EuroIntervention* 2022. DOI: 10.4244/EIJ-D-22-00914








Single-digit gradients.

Protect your patient's future. Minimize the risk of patient-prosthesis mismatch, even in patients with small annuli.



Supra-annular leaflets help you deliver **large EOAs** and **low mean gradients**.

See the evidence.





ACURATE neo2 mean aortic gradients at 30 days in the PMCF study: 8.6mmHg. ACURATE neo2 mean effective orifice area at 30 days in the PMCF study: 1.6 sq. cm³

- Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 Valve System for transcatheter aortic valve implantation: 30-day and 1-year outcomes. *Clin Res Cardiol.* 2021;110:1912-1920.
- Early neo2 Registry. Full Core-Lab Results of TAVI with the New ACURATE neo2 Valve. TVT Congress. Presenter: Andreas Rück. July 20, 2021.
- Kim W., et al; Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, *EuroIntervention* 2022. DOI: 10.4244/EIJ-D-22-00914



Advanced PVL performance.

Protect against PVL with the ACURATE neo2 Valve's advanced sealing skirt:



- * At 30-days, Echocardiographic and CT imaging independently core lab adjudicated
- Kim W., et al; Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, *EuroIntervention* 2022. DOI: 10.4244/EIJ-D-22-00914



Active PVseal™ conforms to native valve annulus



ACURATE neo2™
Aortic Valve System



Unrestricted design

Unrestricted coronary access.

Lower-risk TAVI requires preserved future access.¹
STEMI following TAVI resulted in:

- **4x higher PCI failure rate**
- **33% increased mortality rate²**

100%

ACURATE neo™
Valve platform

100% successful
coronary
cannulation
n = 72

82%

Evolut™ R/PRO

82% successful
coronary
cannulation
n = 123


99%

SAPIEN

99% successful
coronary
cannulation
n = 96

1. Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent (RE ACCESS); NCT04026204. *J Am Coll Cardiol Interv.* 2020.

2. Faroux L, et al. ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. "https://www.jacc.org/journal/jacc" *J Am. Coll. Cardiol.* 2021 May, 77 (17) 2187 -2199.



Unrestricted design

Long-term hemodynamic function.¹

Reduce the risk of valve deterioration and improve long-term cardiac function with a self-expanding, supra-annular design.²

Excellent durability.³

Supra-annular leaflets treated with BioFix™ anti-calcification process are designed with your patient's lifetime in mind.⁴

Accelerated wear testing equivalent to 25 years demonstrated robust wear resistance and excellent hydrodynamic performance³

1. Siqueira DA, Simonato M, Ramos AA, et al. Mid- to long-term clinical and echocardiographic outcomes after transcatheter aortic valve replacement with a new-generation, self-expandable system. *Catheter Cardiovasc Interv.* 2021.

2. Flameng, W, et al. Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves. *Circulation.* 2010; 121:2123-2129.

3. Sathanathan et al., Long-Term Durability of the Next-Generation Acurate neo 2, *Am. Coll. Cardiol. Interv.* 2020 JACC, Vol. 14, NO. 5, 2021 MARCH 8, 2021:583-92.

4. Anderson-Cunanan C et al, Calcification Assessment of the BSC-Symetis Valve Leaflet Material Treated with the Biofix™ Process *Am. Coll. Cardiol. Interv.* 2019, JACC CI, Vol. 12, NO. 4, 2019 FEB 2019, 535-936.




ACURATE neo2™
Aortic Valve System

 Precise procedures

Smooth deliverability.

Expect uncompromised deliverability even in small and tortuous anatomies with low-profile iSLEEVE™* Expandable Introducer Sheath and intuitive, top-down deployment with the ACURATE neo2™ Valve.

 Superior device success among patients with horizontal aortas:



* The iSLEEVE Expandable Introducer Sheath is indicated for vessels ≥ 5.5mm.
1. Gallo F, Gallone G, Kim W-K, et al. Horizontal aorta in transcatheter self-expanding valves: Insights from the HORSE International Multicentre Registry. *Circ Cardiovasc Interv.* 2021;14(9):e010641.


 Precise procedures

Predictable alignment.



ACURATE neo2™ was the only valve to **100%** avoid moderate or severe commissural misalignment.¹

Precise positioning.

Easy-to-spot radiopaque positioning marker ensures enhanced visualization for delivering short procedures and high success rates.²



1. Bieliauskas G, Wong I, Bajoras V, et al. Patient-specific implantation technique to obtain neo-commissural alignment with self-expanding transcatheter aortic valves. *JACC Cardiovasc Interv.* 2021;14(19):2097-2108.
2. Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. *Clin Res Cardiol.* 2021;110(12):1912-1920.
3. Kim W., et al; Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, *EuroIntervention* 2022. DOI: 10.4244/EIJ-D-22-00914



Ordering Information

Ref/Catalog Number	Description	Units
ACURATE neo2 Aortic Valves		
SYM-SV23-004	ACURATE neo2 Aortic Valve S	1
SYM-SV25-004	ACURATE neo2 Aortic Valve M	1
SYM-SV27-004	ACURATE neo2 Aortic Valve L	1
ACURATE neo2 Transfemoral Delivery System and Loading Kit		
SYM-DS-010	ACURATE neo2 Transfemoral Delivery System	1
SYM-AC-010	ACURATE neo2 Loading Kit	1
ACURATE neo2 Aortic Valve Generic Bundle Codes		
BUN67NEO2DSTF	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit	
BUN67NEO2DSTFIS14	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLLEEVE	
BUN67NEO2IS14SAF	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLLEEVE + SAFARI ²	
BUN67NEO2ISSAFSEN	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLLEEVE + SAFARI ² + SENTINEL™	



All trademarks are property of their respective owner. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Information not for use or distribution in France. Illustrations for information purposes – not indicative of actual size or clinical outcome. All photographs taken by Boston Scientific.

SH-809013-AE

CE 0344

Boston Scientific
Advancing science for life™

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.